FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations ...Middle East

SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for patients with locally advanced or metastatic non-small cell...

Hence then, the article about fda grants breakthrough therapy designation to sunvozertinib for the first line treatment of patients with advanced non small cell lung cancer harboring egfr exon 20 insertion mutations was published today ( Sunday 07/04/2024 - 02:13 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations )

Also on site :

• As Colorado’s wildfire threat grows, Douglas County turns to biochar as ‘next level’ mitigation tool
• One of NYC’s Most Unexpected New Attractions Is Under Times Square
• 'Brady Bunch' Mom Florence Henderson Was in Talks for Wild Reboot Before Her Death